cortisol and glp-1 Insights into a possible role of glucagon-like peptide-1 receptor agonists in the treatment of depression | Pharmacological Reports Cortisol vs. GLP-1 meds: The

According to the Diabetes Atlas released by the International Diabetes Federation (IDF), the prevalence of diabetes among adults aged 20 to 79 around the world has reached 11.1%, and about 589 million people have been affected ( Although intensified glycemic control, blood pressure management, and inhibition of the reninangiotensin system (RAS) can slow DKD progression, its clinical course remains highly heterogeneous

Shor, R

References Gnoni A, Longo S, Gnoni GV, Giudetti AM

Beyond metabolic benefits, GLP-1 RAs exhibit cardioprotective effects, reducing the risk of cardiovascular events such as stroke and myocardial infarction [53]